AT552846T - Verbesserter grippeimpfstoff - Google Patents

Verbesserter grippeimpfstoff

Info

Publication number
AT552846T
AT552846T AT06821622T AT06821622T AT552846T AT 552846 T AT552846 T AT 552846T AT 06821622 T AT06821622 T AT 06821622T AT 06821622 T AT06821622 T AT 06821622T AT 552846 T AT552846 T AT 552846T
Authority
AT
Austria
Prior art keywords
improved
flu vaccine
flu
vaccine
Prior art date
Application number
AT06821622T
Other languages
English (en)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US74257405P priority Critical
Priority to US74253005P priority
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to PCT/IL2006/001403 priority patent/WO2007066334A1/en
Publication of AT552846T publication Critical patent/AT552846T/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
AT06821622T 2005-12-06 2006-12-06 Verbesserter grippeimpfstoff AT552846T (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US74257405P true 2005-12-06 2005-12-06
US74253005P true 2005-12-06 2005-12-06
PCT/IL2006/001403 WO2007066334A1 (en) 2005-12-06 2006-12-06 Improved influenza vaccine

Publications (1)

Publication Number Publication Date
AT552846T true AT552846T (de) 2012-04-15

Family

ID=37776792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06821622T AT552846T (de) 2005-12-06 2006-12-06 Verbesserter grippeimpfstoff

Country Status (9)

Country Link
US (1) US7914797B2 (de)
EP (1) EP1968632B1 (de)
AT (1) AT552846T (de)
AU (1) AU2006322907B2 (de)
CA (1) CA2632483C (de)
DK (1) DK1968632T3 (de)
ES (1) ES2385842T3 (de)
PT (1) PT1968632E (de)
WO (1) WO2007066334A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976559B1 (de) * 2006-01-27 2017-01-04 Novartis Influenza Vaccines Marburg GmbH Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
KR101580660B1 (ko) 2007-08-02 2015-12-28 바이오앤드백스 파마슈티칼즈, 리미티드. 다중체 다중-에피토프 인플루엔자 백신
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2185196B1 (de) * 2007-08-27 2014-06-11 Longhorn Vaccines & Diagnostics, LLC Immunogene zusammensetzungen und verfahren
US20110027315A1 (en) * 2007-09-07 2011-02-03 Allen Harmsen Protein cages and their uses
WO2009128950A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP3009145A1 (de) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Impfstoffe gegen das grippevirus und ihre verwendungen
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
WO2011103453A2 (en) * 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
PL222497B1 (pl) 2009-06-26 2016-08-31 Instytut Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
SG184804A1 (en) 2010-04-30 2012-11-29 Temasek Life Sciences Lab Ltd Universal vaccine against h5n1 lineages
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
SG11201400743VA (en) 2011-09-20 2014-04-28 Sinai School Medicine Influenza virus vaccines and uses thereof
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN105263516A (zh) 2012-12-18 2016-01-20 西奈山伊坎医学院 流感病毒疫苗及其用途
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2015006384A1 (en) * 2013-07-09 2015-01-15 Texas Tech University System Universal influenza vaccine
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
IL101639D0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
IL109664D0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
WO1998023735A1 (en) 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Immune responses using compositions containing stress proteins
JP5132851B2 (ja) 1997-08-05 2013-01-30 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー)Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw(Vib Vzw) 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
IL127331D0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
ES2295175T3 (es) * 2000-06-23 2008-04-16 Wyeth Holdings Corporation Ensamblaje de particulas similares al virus (vlp) de la gripe de tipo salvaje y quimericas.
US20040223976A1 (en) 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine

Also Published As

Publication number Publication date
PT1968632E (pt) 2012-07-16
AU2006322907A1 (en) 2007-06-14
CA2632483C (en) 2014-11-25
AU2006322907B2 (en) 2012-08-02
US20090304730A1 (en) 2009-12-10
EP1968632A1 (de) 2008-09-17
WO2007066334A9 (en) 2009-09-11
ES2385842T3 (es) 2012-08-01
EP1968632B1 (de) 2012-04-11
WO2007066334A1 (en) 2007-06-14
US7914797B2 (en) 2011-03-29
CA2632483A1 (en) 2007-06-14
DK1968632T3 (da) 2012-07-16

Similar Documents

Publication Publication Date Title
DE602006017614D1 (de) Anastomoseverbunddichtung
AT408603T (de) Pyrazolylcarboxanilide
AT551802T (de) Anbieter-streckenzustand-überbrückung
DE602005017262D1 (de) Handstaubsauger
DE602006007822D1 (de) Nrate
AT523504T (de) 1-thio-d-glucitolderivate
AT541571T (de) Diarylhydantoin-verbindung
DE602006020094D1 (de) Ösennahtanker
AT474271T (de) Dma-deskriptoren-warteschlangen-lese-und-cache- schreib-zeigeranordnung
DK1968631T3 (da) Vaccine
AT462445T (de) Prrs-impfstoffe
DE602006018394D1 (de) Hybridcopolymere
AT527526T (de) Photonenzählvorrichtung
DE602006015785D1 (de) L-dimension-scatterometrie
AT539711T (de) Hüftpfannenpositionierung
AT437205T (de) Styrylsulfidfarbstoffe
DE602006017807D1 (de) Oberflächeninjizierungsvorrichtung
AT415839T (de) Antiquetsch-klappstuhl
DE602006005805D1 (de) Verwirbelungsanordnung
DE602006006066D1 (de) Ermodulgehäuse
AT444717T (de) Lasermikroporator
AT530519T (de) Cyclobutylaminderivate
DE602006012058D1 (de) Verbessertes elektroblasfaserspinnverfahren
DE602006021647D1 (de) Umbördelvorrichtung
AT477250T (de) Cyanoanthranilamidinsektizide